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bstract
Treatment of primary aldosteronism (PA) aims at preventing or correcting hypertension, hypokalemia and target organ damage. Patients with
ateralized PA and candidates for surgery may be managed by laparoscopic adrenalectomy. Partial adrenalectomy and non-surgical ablation have
o proven advantage over total adrenalectomy. Intraoperative morbidity and mortality are low in reference centers, and day-surgery is warranted
n selected cases. Spironolactone administered during the weeks preceding surgery controls hypertension and hypokalemia and may prevent
ostoperative hypoaldosteronism. In most cases, surgery corrects hypokalemia, improves control of hypertension and reduces the burden of
harmacologic treatment; in about 40% of cases, it resolves hypertension. However, success in controlling hypertension and reversing target organ
amage is comparable with mineralocorticoid receptor antagonists. Informed patient preference with regard to surgery is thus an important factor
n therapeutic decision-making.
 2016 Elsevier Masson SAS. All rights reserved.
eywords: Adrenalectomy; Hyperaldosteronism; Treatment outcome; Guiding factors
ésumé
Le traitement de l’hyperaldostéronisme primaire vise à prévenir ou corriger l’hypertension, l’hypokaliémie et le retentissement direct sur les
rganes cibles. Les patients avec une hypersécrétion latéralisée d’aldostérone et candidats à la chirurgie peuvent bénéficier d’une surrénalec-
omie laparoscopique. La surrénalectomie partielle et les ablations non chirurgicales n’ont pas d’avantage avéré par rapport à la surrénalectomie
otale. La morbimortalité peropératoire est faible dans les centres de référence, autorisant la chirurgie ambulatoire dans des cas sélectionnés.
’administration de spironolactone dans les semaines précédant la chirurgie permet de contrôler l’HTA et l’hypokaliémie, et peut-être de prévenir
’hypoaldostéronisme postopératoire. Dans la plupart des cas, la chirurgie corrige l’hypokaliémie, améliore le contrôle de la pression artérielle et
iminue la charge des traitements pharmacologiques ; dans environ 40 %, elle guérit l’hypertension. Toutefois, le contrôle de l’hypertension et la
éversibilité du retentissement sur les organes cibles sont comparables avec les antagonistes du récepteur des minéralocorticoïdes. Les préférences
u patient pour ou contre la chirurgie sont donc un élément important de la 
 2016 Elsevier Masson SAS. Tous droits re´serve´s.
ots clés : Surrénalectomie ; Hyperaldostéronisme ; Résultat thérapeutique ; Lignes
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Without potassium supplementation, kalemia diminishes by a
mean 0.5–1 mmol/l during adrenalectomy compared to preope-
rative values [18], and kalemia should therefore be normalizedO. Steichen et al. / Annales d’E
This section deals with adrenalectomy in lateralized primary
ldosteronism (PA). Indications depend on the risk/benefit pro-
le in comparison with medical management, and on patient
reference and overall cost considerations between the two
pproaches.
.  Adrenal  surgery  in  PA
.1.  Technical  aspects
.1.1.  Open  or  laparoscopic  surgery
Except for adrenocortical carcinoma, which is exceptional,
he adrenal lesions causing lateralized PA are small and benign,
aking them ideal for laparoscopic surgery [1]. Laparoscopic
drenalectomy entails fewer perioperative complications (pari-
tal, infectious, respiratory or cardiovascular) than open surgery
nd allows shorter hospital stay [2].
R6.1  -  When  surgery  is  indicated,  laparoscopic
rather than  open  surgery  is  recommended.
(Strong, evidence  +++)
.1.2.  Laparoscopic  approach
The lateral transperitoneal approach provides better operative
ite exposure, while posterior retroperitoneoscopy avoids the
roblems of adherences from previous surgeries and may reduce
ospital stay [3]. Laparoscopic adrenalectomy usually requires
 or 4 entry points, although an isolated transumbilical approach
s also possible and less invasive [4].
Robot-assisted surgery is possible and without added risk, but
xpensive and without proven benefit over simple laparoscopic
urgery [5–7].
R6.2  -  We  recommend  a  trans-  or  retro-
peritoneal  approach,  with  or  without  robot-
assistance,  according  to  the  patient’s  proﬁle  and
the surgeon’s  preferences.
(Strong,  evidence  ++)
.1.3.  Total  or  partial  adrenalectomy
Adenomectomy is possible and entails no extra complications
ompared to total adrenalectomy [8,9]. Operative times are sim-
lar, although intraoperative blood loss is significantly greater in
denectomy, without, however, requiring supplementary trans-
usion [8,9]. The rationale supporting conservative surgery,
owever, is unclear in lateralized PA, which never shows recur-
ence in the contralateral adrenal; moreover, 10–25% of patients
ave several adjacent nodules, whether or not visible on pre-
perative imaging, and there is no way of knowing which is
esponsible for the PA, entailing a risk of incomplete treatment
f part of the adrenal is spared [10].
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R6.3  -  Except  in  special  cases,  total  adrenalec-
tomy is  indicated  in  lateralized  PA.
(Weak,  evidence  +)
.2.  General  complications
Mean operative time, in a specialized center with an
xperienced surgeon, is 1–2 h [11,12], with cross-over to
pen surgery never more than 5% [1]. Perioperative mor-
ality is less than 0.5%, and perioperative morbidity ranges
etween 5 and 15%, mainly comprising minor complications:
ransient parietal hypotonia or hypoesthesia [1,2,11]. Severe
omplications (hemorrhage requiring transfusion, cardiac or
espiratory complications) concern less than 2% of cases
1,2,11]. However, the complications rate depends or the sur-
ical team’s experience, and higher severe complications rates
ere reported outside of specialized centers [13].
R6.4  -  Adrenalectomy  should  be  performed  by
an experienced  surgeon  in  a  reference  center.
(Weak, evidence  +)
In specialized centers, mean hospital stay is 3 days [1].
iven the low risk of complications in such centers, laparo-
copic adrenalectomy may be performed on an outpatient basis
n well-selected cases: age < 65 years, without significant cardiac
omorbidity, hypertension managed by at most 3 drugs, proce-
ure performed early in the day, and residence within 30 min of
he hospital [14–16].
R6.5  -  In  references  centers,  selected  patients
may be  managed  on  an  outpatient  basis.
(Weak, evidence  ++)
.3.  Speciﬁc  complications  and  short-term  follow-up
Systolic pressure increases by a mean 20–30 mmHg above
sual levels during laparoscopic adrenalectomy for lateralized
A, requiring antihypertensive treatment in 45% of cases [17].ust ahead of surgery. Spironolactone during the weeks before
urgery may also reduce the risk of postoperative hyperaldos-
eronism by neutralizing aldosterone inhibition in the normal
drenal.
2 Endocrinologie 77 (2016) 220–225
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R6.9  -  Postoperative  hormone  analysis  is  recom-
mended in  case  of  persistent  hypertension  or
hypokalemia, and  suggested  in case  of  clinical  and
biological  cure  of  PA.
(Evidence  +)
R6.10  -  Speciﬁc  clinical  and  biological  follow-
up should  be  ceased  in  patients  with  normal
blood pressure  and  kalemia  at  1  year  without
treatment. In  case  of  persistent  hypertension,
follow-up  should  be  conducted  according  to  post-
operative  diagnosis:  essential  hypertension  or
persistent  PA.
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R6.6  - We  recommend  preoperative  mine-
ralocorticoid  receptor  antagonist  treatment  to
control  hypertension  and  hypokalemia  and  reduce
the risk  of  postoperative  functional  mineralo-
corticoid insufﬁciency.  Preoperative  potassium
supplementation  is  recommended  in  case  of  per-
sistent  hypokalemia.
(Strong,  evidence  +)
Postoperative hyperkalemia due to functional mineralocorti-
oid insufficiency in the contralateral adrenal was nevertheless
eported in 15–30% of cases despite preventive prescription of
reoperative spironolactone [19,20]. It was generally moderate
nd transient. Spironolactone and potassium supplementation
hould be interrupted at surgery to reduce this risk, and
alemia should be checked postoperatively, especially in case
f chronic kidney failure [20]. Even so, however, up to 5%
f patients may require prolonged postoperative fludrocortisone
reatment [19].
R6.7  -  Mineralocorticoid  receptor  antagonists
and potassium  supplementation  should  be  inter-
rupted at  surgery  to  avoid  hyperkalemia  induced
by functional  mineralocorticoid  insufﬁciency.  We
also recommend  interrupting  low-salt  diet  and
antihypertensives  in  the  absence  of  other  indica-
tions, to  reduce  the  risk  of  fall  in  blood  pressure
due to  functional  mineralocorticoid  insufﬁciency.
(Strong, evidence  +)
R6.8  -  Blood  pressure  and  kalemia  should
be monitored  postoperatively.  Antihypertensive
treatment  should  be  resumed  in  case  of  post-
operative hypertension.  Fludrocortisone  should
be administered  in  case  of  persistent  symptomatic
hyperkalemia  or  hypotension.
(Strong,  evidence  +)
.4.  Medium-to-long-term  follow-up
Postoperative distinctions between histological types of PA
re without clinical impact, but may be contributive epi-
emiologically. In persistent postoperative hypertension or
ypokalemia, hormonal analysis may diagnose persistent PA
nd guide further treatment. If hypertension and hypokalemia
ave resolved, there is no individual benefit of hormonal ana-
ysis, although it may be useful for objectively assessing cure.
atients with normal blood pressure and kalemia at 1 year with-
ut treatment can be deemed cured.
t
fi
a(Weak,  evidence  +)
.  Surgical  outcomes  in  lateralized  PA
Surgical outcomes assessment was based on a systematic
eview of series of more than 50 patients; only those pub-
ished since 2000 were included, so as to represent the outcomes
f laparoscopic surgery in present-day patients [10]. Older
eries concerned open surgery, and patients differed from recent
eries as hypertension was defined by an outdated threshold of
 160/100 mmHg and the aldosterone-to-renin ratio was not used
n screening. The limitations of the included series were that they
id not compare surgical versus medical treatment, and assessed
utcomes only in the medium term (a few months to a few years).
.1.  Hyperaldosteronism  and  hypokalemia
By definition, unilateral adrenalectomy cures hyperaldos-
eronism in all cases of lateralized PA. In practice, 5–10% of
perated patients show persistent hyperaldosteronism, as their
A was non-lateralized [10]. Misdiagnosis of lateralization is
hus possible, even with adrenal vein sampling [21]; the fre-
uency may be overestimated, as postoperative hormonal assay
s often restricted to patients not showing the expected clinical
enefit from surgery. Hypokalemia resolved in more than 95%
f cases in all series [10].
.2.  Blood  pressure
Cure rates for hypertension are around 40%, with wide
ariation between series [10]. Patients who are not actually
ured generally show considerable postoperative improvement,
ith significant reductions in blood pressure (20–40 mmHg
or systolic BP) and medication (reduction of 1–2 therapeu-
ic classes). The proportion of patients without obvious benefit
anges between 0 and 25%.Numerous predictive factors have been suggested for persis-
ent postoperative hypertension [10]. Factors emerging as signi-
cant from at least 1 multivariate analysis comprise male gender,
ge, familial history of hypertension, duration of hypertension,
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ication or have a strong aversion to surgery are going to preferO. Steichen et al. / Annales d’E
lood pressure elevation requiring a larger number of treatments,
levated body-mass index, elevated kalemia, low glomerular
ltration rate, elevated urinary aldosterone divided by plasma
enin concentration, and infraclinical target organs damage.
These prognostic factors, however, are of very little relevance
o selection for surgery [10,22]. Firstly, studies lacked power
nd showed poor reproducibility. Secondly, the difference in
uccess rates associated with these factors was low, even when
tatistically significant: typically, patients with multiple factors
f poor prognosis still had a 25% chance of complete cure by
urgery, compared to 40% in the overall population. Thirdly,
hose whose hypertension was not cured nevertheless showed
onsiderably reduced blood pressure and/or medication [23].
nd fourthly, there may be benefit regardless of blood pressure
eduction, as normalized aldosterone secretion benefits target
rgans.
There have been no studies directly comparing blood-
ressure impact between adrenalectomy and medical treatment
n lateralized PA. One study, however, suggested that kalemia
ormalization and blood-pressure reduction are comparable
etween spironolactone treatment and surgery, even in the long
erm [24].
.3.  Cardiovascular,  renal  and  metabolic  impact
.3.1.  Infraclinical  cardiovascular  damage
Many studies reported that left ventricle hypertrophy
egressed after adrenalectomy. Those with long-term follow-
p suggested that spironolactone provided the same effect, but
ore slowly [25]. Likewise, pulse-wave velocity and carotid
ntima-media thickness, which are increased in PA, improved
fter surgery [26,27] and spironolactone again provided the same
enefit, but more slowly [28].
.3.2. Cardiovascular  events
A long-term prospective study compared 54 PA patients man-
ged surgically (unilateral PA) or medically (uni- or bilateral PA)
nd 323 matched essential hypertension patients. Incidence did
ot differ for the composite endpoint of myocardial infarction,
oronary revascularization, stroke or sustained arrhythmia at a
ean 7.4 years’ follow-up between PA and essential hyperten-
ion or between PA managed by surgery or by spironolactone
29]. A similar study used a slightly different composite endpoint
f acute coronary event, persistent arrhythmia or hospital admis-
ion for heart failure; incidence over a mean 12 years’ follow-up
as slightly greater in 270 PA patients with specific surgical
r medical treatment than in 810 matched essential hyperten-
ion patients [30]. The differing result may have been due to the
nclusion of hospital admissions for heart failure, unlike in the
revious study.
.3.3. Infraclinical  renal  damage
Relative glomerular hyperfiltration and microalbuminuria in
A are reversible after surgery or spironolactone treatment [31].
 short-term (1 year) study suggested superiority of surgery over
edical treatment with regard to glomerular filtration rate and
m
p
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roteinuria [32]. However, long-term (> 5 years) renal benefit of
edical treatment seems not inferior to surgery [33–35].
.3.4. Metabolic  impact
There are arguments pointing to insulin resistance in PA,
eversible with specific treatment. The clinical studies, however,
emonstrate neither increased prevalence of lipid or glucose
etabolism disorder nor improvement with PA-specific treat-
ent [36–38].
.4.  Quality  of  life/satisfaction
One study reported that the impaired quality of life of
nilateral PA patients was improved by adrenalectomy [39].
pironolactone seems to have the same effect, at a longer term,
n all forms of PA [40].
.5.  Treatment  costs
A rough cost/benefit analysis showed that, in 50 year-old
nilateral PA patients, adrenalectomy was more economical
n cost terms than life-long medication, if it achieved 35%
ure of hypertension and 50% improvement in control [41].
nother analysis suggested that adrenal vein sampling followed
y surgery when PA proved lateralized was less expensive than
ystematic medical treatment without adrenal vein sampling,
hen life expectancy exceeded 25 years; the model’s hypothe-
es, however, were open to criticism, with a high proportion of
nilateral PA (50%) in patients undergoing adrenal vein samp-
ing, an optimistic rate of hypertension cure (48%) and higher
osts than would be applicable in France: $330 per year for
pironolactone 75 mg, $2200 for adrenal vein sampling, and
8400 for surgery [42].
.  Indications  for  surgery  in  lateralized  PA
The unquestionable advantage of adrenalectomy over medi-
al treatment consists in the lower long-term economic cost and
sychological burden of medication. The disadvantages consist
n a greater immediate cost outlay, and in operative risk, which,
hough low, is undeniable.
Young patients have long-life expectancy and low anesthesia-
elated risk, and are thus ideal candidates for surgery. Patients
ith poor spironolactone tolerance or issues of adherence are
lso good candidates.
Conversely, older patients have shorter life expectancy and
reater surgical risk; they more often present cardiovascular
nd/or kidney disease requiring ACE inhibitors, angiotensin II
eceptor blockers, diuretic (including spironolactone) or beta-
locker treatment. Such treatments will not be stopped, even if
ypertension is cured. Likewise, patients who agree to take med-edical management.
Finally, treatment decision-making largely depends on the
atient’s preferences, and should therefore be taken in common
fter clear impartial information.
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R6.11  -  The  decision  to  operate  should  be  taken
in common  with  the  patient  after  information  dea-
ling with  at  least  the  following:
• when  an  adrenal  gland  nodule  is  seen  on  ima-
ging, it  is  benign,  with  zero  risk  of  malignant
degeneration;
• in  the  present  state  of  knowledge,  medical  and
surgical treatment  are  comparable  in  terms  of
correcting  hypokalemia,  lowering  blood  pres-
sure and  preventing  cardiovascular  and  renal
morbidity and  mortality;
• PA-speciﬁc  medical  treatment  is  not  always  well
tolerated, and  is  life-long;
• surgery  is  possible  at  any  time,  including  after
a trial  of  medical  treatment,  in  case  of  unilateral
PA (which  may  need  conﬁrmation  on  adrenal
vein sampling);
• surgery  generally  allows  a  few  drugs  to  be
discontinued (including  the  PA-speciﬁc  medica-
tion), but  antihypertensive  treatment  has  to  be
continued life-long  in  more  than  half  of  cases.
(Weak, evidence  +)
R6.12  -  Treatment  decision  should  be  discussed
prior to  adrenal  vein  sampling,  which  is  point-
less in  patients  unwilling  to  undergo  surgery,  and
patients  should  be  afforded  a medical  trial  period
of a  few  weeks  if  they  so  wish  before  deciding  on
surgery.
(Weak,  evidence  +)
.  Non-surgical  interventions
Alternatives to surgery for adrenal gland treatment in uni-
ateral PA have been described: cryoablation, thermoablation,
mbolization, ethanol injection, or radiofrequency ablation.
hey are less invasive than surgery, but risks and outcomes
notably in the long term) are uncertain. The main contraindi-
ations are large (> 2 to 4 cm) lesions and lesions inaccessible
o laparoscopy or in contact with a fragile structure such as the
orta or kidney [10].
R6.13  -  Alternative  interventions  in  place  of
adrenalectomy should  be  performed  only  within
an assessment  study.
(Weak,  evidence  +)rinologie 77 (2016) 220–225
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